Previous 10 | Next 10 |
2023-08-02 07:34:29 ET Repligen press release ( NASDAQ: RGEN ): Q2 GAAP EPS of $0.53 beats by $0.21 . Revenue of $159.2M (-23.3% Y/Y) misses by $6.72M . Adjusts full year revenue guidance to range of $635-$665 million. Gross margin is expected to be 49.5%-5...
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corpo...
2023-08-01 13:09:25 ET Repligen ( NASDAQ: RGEN ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is $0.48 (-47.3% Y/Y) and the consensus Revenue Estimate is $165.92M (-20.1% Y/Y). Over the last 2 yea...
2023-07-30 11:23:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund® (the Fund) appreciated 3.58% (Institutional Shares) in the ...
2023-07-25 07:30:47 ET Despite posting better than expected financials for Q2 2023, Danaher Corporation ( NYSE: DHR ) slipped ~5% pre-market Tuesday as the U.S. life sciences company lowered its full-year outlook amid falling COVID-related revenue. Danaher’s ( DHR ...
2023-07-21 11:43:42 ET Sartorius AG ( OTCPK:SARTF ) traded sharply higher on Friday, rallying the shares of its U.S. peers, after the German life sciences company posted its Q2 2023 results, indicating a gradual recovery following a post-pandemic contraction in demand. Notable gaine...
2023-07-20 13:08:32 ET Wells Fargo launched its coverage of Repligen Corporation ( NASDAQ: RGEN ) with an Overweight rating and a $185 price target on Thursday, noting that the life sciences company reflects overly negative investor concerns over its near-term headwinds. The ana...
WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2, 2023. The Company will issue a press release before the market opens and will host a conference call ...
2023-07-18 11:35:14 ET Summary Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use products for biopharma manufacturing. The company is ex...
2023-06-28 16:10:16 ET Summary With growth prospects, ongoing deleveraging and margin expansion efforts, acquisition value realization and 85% recurring revenue mix, Avantor is well positioned to take advantage of the secular life science uptrend. Avantor faces near-term challenge...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...